Nucleus-selective codelivery of proteins and drugs for synergistic antitumor therapy.
Lan YangHuijie MaShan LinYupeng ZhuHui ChenNing ZhangXuli FengPublished in: Chemical science (2022)
Subcellular organelle targeted transport is of great significance for accurately delivering drugs to active sites for better pharmacological effects, but there are still a lot of challenges due to transport problems. In addition, the killing effect of one kind of drug on cells is limited. Therefore, it is necessary to develop a multifunctional nanoplatform that can co-deliver synergistic therapeutic agents. Here, we prepare a simple amphiphilic nanocarrier (LC) with rapid endosomal escape ability for nucleus-selective delivery of hydrophilic active protein deoxyribonuclease I (DNase I) and hydrophobic anticancer drug doxorubicin (DOX). LC has been applied to effectively encapsulate DNase I just by simply mixing their aqueous solutions together. In addition, DOX modified with adamantane groups via a redox-responsive linker is incorporated into the architecture of DNase I nanoformulations through host-guest interaction. This multi-component nanoplatform can quickly escape from the endolysosomes into the cytoplasm and make DNase I and DOX highly accumulate in the nucleus and consequently induce strong synergistic anticancer efficacy both in vitro and in vivo . This work illustrates a new platform for codelivery of proteins and drugs that target subcellular compartments for functions.
Keyphrases
- cancer therapy
- drug delivery
- drug induced
- liquid chromatography
- induced apoptosis
- mental health
- simultaneous determination
- drug release
- mass spectrometry
- cell cycle arrest
- high throughput
- stem cells
- adverse drug
- cell death
- emergency department
- high resolution
- solid phase extraction
- protein protein
- cell therapy
- electronic health record
- single cell